Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell NewsThe antitumour activity of lenvatinib in immunocompetent and immunodeficient mice was compared to determine the role of T cell immunity. The antitumour activity of T cells was analysed by cytokine production and adoptive T cell therapy.
[Pharmacological Research]
6445212 DFS2HFDC items 1 apa 0 default asc 1 165931 https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-72430c79b11f74a5ddd41764a9d0dddf%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22DFS2HFDC%22%2C%22library%22%3A%7B%22id%22%3A6445212%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Lu%20et%20al.%22%2C%22parsedDate%22%3A%222021-08-17%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ELu%2C%20M.%2C%20Zhang%2C%20X.%2C%20Gao%2C%20X.%2C%20Sun%2C%20S.%2C%20Wei%2C%20X.%2C%20Hu%2C%20X.%2C%20Huang%2C%20C.%2C%20Xu%2C%20H.%2C%20Wang%2C%20B.%2C%20Zhang%2C%20W.%2C%20Li%2C%20Z.%2C%20Feng%2C%20X.%2C%20Zheng%2C%20J.%2C%20%26amp%3B%20Zhang%2C%20Q.%20%282021%29.%20Lenvatinib%20enhances%20T%20cell%20immunity%20and%20the%20efficacy%20of%20adoptive%20chimeric%20antigen%20receptor-modified%20T%20cells%20by%20decreasing%20myeloid-derived%20suppressor%20cells%20in%20cancer.%20%3Ci%3EPharmacological%20Research%3C%5C%2Fi%3E%2C%20105829.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.phrs.2021.105829%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.phrs.2021.105829%3C%5C%2Fa%3E%20%3Ca%20title%3D%27Cite%20in%20RIS%20Format%27%20class%3D%27zp-CiteRIS%27%20href%3D%27https%3A%5C%2F%5C%2Fwww.stemcellsciencenews.com%5C%2Fwp-content%5C%2Fplugins%5C%2Fzotpress%5C%2Flib%5C%2Frequest%5C%2Frequest.cite.php%3Fapi_user_id%3D6445212%26amp%3Bitem_key%3DDFS2HFDC%27%3ECite%3C%5C%2Fa%3E%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Lenvatinib%20enhances%20T%20cell%20immunity%20and%20the%20efficacy%20of%20adoptive%20chimeric%20antigen%20receptor-modified%20T%20cells%20by%20decreasing%20myeloid-derived%20suppressor%20cells%20in%20cancer%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mengmeng%22%2C%22lastName%22%3A%22Lu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xiaokang%22%2C%22lastName%22%3A%22Zhang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xiaoge%22%2C%22lastName%22%3A%22Gao%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shishuo%22%2C%22lastName%22%3A%22Sun%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xiaohuan%22%2C%22lastName%22%3A%22Wei%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xiaolei%22%2C%22lastName%22%3A%22Hu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chao%22%2C%22lastName%22%3A%22Huang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Heng%22%2C%22lastName%22%3A%22Xu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bixi%22%2C%22lastName%22%3A%22Wang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wei%22%2C%22lastName%22%3A%22Zhang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zhen%22%2C%22lastName%22%3A%22Li%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xinhui%22%2C%22lastName%22%3A%22Feng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Junnian%22%2C%22lastName%22%3A%22Zheng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Qing%22%2C%22lastName%22%3A%22Zhang%22%7D%5D%2C%22abstractNote%22%3A%22Background%5CnLenvatinib%2C%20a%20tyrosine%20kinase%20inhibitor%2C%20has%20been%20approved%20for%20the%20treatment%20of%20several%20cancers.%20However%2C%20its%20regulatory%20activity%20and%20related%20mechanisms%20on%20T%20cell%20antitumour%20immunity%20need%20to%20be%20further%20investigated.%5CnMethods%5CnThe%20antitumour%20activity%20of%20lenvatinib%20in%20immunocompetent%20and%20immunodeficient%20mice%20was%20compared%20to%20determine%20the%20role%20of%20T%20cell%20immunity.%20The%20antitumour%20activity%20of%20T%20cells%20was%20analysed%20by%20cytokine%20production%20and%20adoptive%20T%20cell%20therapy.%20The%20immunosuppressive%20effects%20of%20MDSCs%20on%20T%20cells%20were%20determined%20by%20detecting%20cytokine%20production%20in%20T%20cells%20after%20being%20cocultured%20with%20MDSCs.%20The%20adjuvant%20immunotherapy%20effect%20of%20lenvatinib%20was%20determined%20by%20combination%20therapy%20with%20CAR-T%20cells%20targeted%20carbonic%20anhydrase%20IX%20%28CAIX%29%20in%20a%20murine%20renal%20cancer%20model.%5CnResults%5CnThe%20antitumour%20activity%20of%20lenvatinib%20was%20greater%20in%20immunocompetent%20mice%20than%20in%20immunodeficient%20mice%20and%20was%20attenuated%20by%20CD8%2B%20T%20cell%20depletion.%20Lenvatinib%20increased%20proliferation%2C%20tumour%20infiltration%20and%20antitumour%20activity%20of%20T%20cells.%20Importantly%2C%20adoptive%20transfer%20of%20lenvatinib-treated%20T%20cells%20showed%20a%20long-term%20antitumour%20response%20in%20vivo.%20Mechanistically%2C%20lenvatinib%20upregulated%20T%20cell-related%20chemokines%20%28CXCL10%20and%20CCL8%29%20in%20tumours%20and%20decreased%20the%20frequency%20and%20immunosuppressive%20activity%20of%20MDSCs.%20Furthermore%2C%20lenvatinib%20enhanced%20the%20efficacy%20of%20CAR-T%20cells%20in%20a%20murine%20renal%20cancer%20model.%5CnConclusion%5CnOur%20study%20revealed%20novel%20antitumour%20mechanisms%20of%20lenvatinib%20by%20enhancing%20T%20cell-mediated%20antitumour%20immunity.%20These%20findings%20are%20of%20great%20significance%20for%20guiding%20the%20clinical%20use%20of%20lenvatinib%20and%20provide%20a%20good%20candidate%20for%20future%20combination%20therapy%20with%20T-cell%20therapies%20or%20other%20immunotherapies.%22%2C%22date%22%3A%22August%2017%2C%202021%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.phrs.2021.105829%22%2C%22ISSN%22%3A%221043-6618%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.sciencedirect.com%5C%2Fscience%5C%2Farticle%5C%2Fpii%5C%2FS1043661821004138%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222021-08-20T16%3A08%3A18Z%22%7D%7D%5D%7D
Lu, M., Zhang, X., Gao, X., Sun, S., Wei, X., Hu, X., Huang, C., Xu, H., Wang, B., Zhang, W., Li, Z., Feng, X., Zheng, J., & Zhang, Q. (2021). Lenvatinib enhances T cell immunity and the efficacy of adoptive chimeric antigen receptor-modified T cells by decreasing myeloid-derived suppressor cells in cancer. Pharmacological Research, 105829. https://doi.org/10.1016/j.phrs.2021.105829 Cite
